Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe.
Adult
Cervix Uteri
/ pathology
Coinfection
/ diagnosis
DNA, Viral
/ isolation & purification
Female
Guadeloupe
/ epidemiology
Human papillomavirus 16
/ genetics
Human papillomavirus 18
/ genetics
Humans
Incidence
Middle Aged
Papillomavirus Infections
/ diagnosis
Papillomavirus Vaccines
/ administration & dosage
Retrospective Studies
Uterine Cervical Neoplasms
/ epidemiology
Uterine Cervical Dysplasia
/ epidemiology
Caribbean
Cervical cancer
Guadeloupe
Human papilloma virus
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
16
11
2020
accepted:
16
02
2021
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Cervical cancer is the fourth cancer worldwide. The Human Papilloma Virus is responsible for 99% of the cases but the distribution of its genotypes varies among populations. We aimed to identify HPV genotypes distribution in women with grade 2/3 cervical intraepithelial dysplasia or invasive cervical cancer in Guadeloupe, a French Caribbean territory with a population mainly of African descent. We used paraffin-embedded tumors for viral DNA extraction from women diagnosed between 2014 and 2016 and identified by the population-based cancer registry. The HPV Genotyping was performed with the InnoLIPA HPV Genotyping Extra kit®. Overall, 213 samples out of the 321 eligible records were analyzed. The HPV status was positive for 94% of the cases. The five most common oncogenic HPV genotypes were HPV31 (47%), HPV33 (38%), HPV16 (32%), HPV44 (31%) and HPV26 (28%). HPV18 was found in only in 5% of the cases. Among the studied cases, 94% had multiple infections. More than 60% of single infections were HPV16-related, accounting for 35% of HPV16 infections. These results show a different distribution of oncogenic HPVs in Guadeloupe with "31 > 33 > 16" and a high frequency of multiple infections. Despite a lower coverage, the nine-valent vaccine is nevertheless adequate.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is the fourth cancer worldwide. The Human Papilloma Virus is responsible for 99% of the cases but the distribution of its genotypes varies among populations. We aimed to identify HPV genotypes distribution in women with grade 2/3 cervical intraepithelial dysplasia or invasive cervical cancer in Guadeloupe, a French Caribbean territory with a population mainly of African descent.
METHODS
METHODS
We used paraffin-embedded tumors for viral DNA extraction from women diagnosed between 2014 and 2016 and identified by the population-based cancer registry. The HPV Genotyping was performed with the InnoLIPA HPV Genotyping Extra kit®.
RESULTS
RESULTS
Overall, 213 samples out of the 321 eligible records were analyzed. The HPV status was positive for 94% of the cases. The five most common oncogenic HPV genotypes were HPV31 (47%), HPV33 (38%), HPV16 (32%), HPV44 (31%) and HPV26 (28%). HPV18 was found in only in 5% of the cases. Among the studied cases, 94% had multiple infections. More than 60% of single infections were HPV16-related, accounting for 35% of HPV16 infections.
CONCLUSIONS
CONCLUSIONS
These results show a different distribution of oncogenic HPVs in Guadeloupe with "31 > 33 > 16" and a high frequency of multiple infections. Despite a lower coverage, the nine-valent vaccine is nevertheless adequate.
Identifiants
pubmed: 33726684
doi: 10.1186/s12885-021-07940-3
pii: 10.1186/s12885-021-07940-3
pmc: PMC7962384
doi:
Substances chimiques
DNA, Viral
0
Human Papillomavirus Recombinant Vaccine nonavalent
0
Papillomavirus Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
281Références
J Med Virol. 2016 Jul;88(7):1262-70
pubmed: 26680281
BMC Infect Dis. 2014 Jul 16;14:395
pubmed: 25030273
Glob Health Action. 2017;10(1):1337341
pubmed: 28649938
Cancer Causes Control. 2017 Nov;28(11):1333-1340
pubmed: 28948421
Eur J Cancer. 2000 Nov;36(17):2215-20
pubmed: 11072207
J Med Virol. 2020 Jan 12;:
pubmed: 31930525
Int J Oncol. 2009 Jan;34(1):263-71
pubmed: 19082497
Int J Mol Sci. 2018 Sep 11;19(9):
pubmed: 30208597
Biomarkers. 2007 Sep-Oct;12(5):510-22
pubmed: 17701749
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
BMJ Open. 2017 Jul 17;7(7):e015653
pubmed: 28716790
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):785-789
pubmed: 29582635
Int J Infect Dis. 2015 Dec;41:13-6
pubmed: 26597118
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1462-1467
pubmed: 28543620
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
BMC Cancer. 2017 Aug 8;17(1):531
pubmed: 28789619
Sex Transm Infect. 2018 Jun;94(4):263-267
pubmed: 29021405
J Clin Pathol. 1983 Jun;36(6):616-24
pubmed: 6304149
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1274-80
pubmed: 16835323
BMC Med Res Methodol. 2018 Dec 5;18(1):161
pubmed: 30518332
Pathobiology. 2009 May;76(3):141-8
pubmed: 19468254
Int J Cancer. 2007 Aug 1;121(3):621-32
pubmed: 17405118
J Natl Cancer Inst. 2000 Mar 15;92(6):464-74
pubmed: 10716964
J Clin Pathol. 2004 Jan;57(1):68-72
pubmed: 14693839
Int J Cancer. 2000 Feb 15;85(4):486-91
pubmed: 10699919
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nature. 2012 Aug 30;488(7413):S2-3
pubmed: 22932437
Br J Cancer. 2003 Jan 13;88(1):63-73
pubmed: 12556961
J Virol. 1995 May;69(5):3074-83
pubmed: 7707535